Display options
Cite
Ulrich N, Gastmeier P. Where is the difference between an epidemic and a high endemic level with respect to nosocomial infection control measures? An analysis based on the example of vancomycin-resistant Enterococcus faecium in hematology and oncology departments. GMS Hyg Infect Control. 2017;12:Doc14doi: 10.3205/dgkh000299.
Ulrich, N., & Gastmeier, P. (2017). Where is the difference between an epidemic and a high endemic level with respect to nosocomial infection control measures? An analysis based on the example of vancomycin-resistant Enterococcus faecium in hematology and oncology departments. GMS hygiene and infection control, 12Doc14. https://doi.org/10.3205/dgkh000299
Ulrich, Nikos, and Gastmeier, Petra. "Where is the difference between an epidemic and a high endemic level with respect to nosocomial infection control measures? An analysis based on the example of vancomycin-resistant Enterococcus faecium in hematology and oncology departments." GMS hygiene and infection control vol. 12 (2017): Doc14. doi: https://doi.org/10.3205/dgkh000299
Ulrich N, Gastmeier P. Where is the difference between an epidemic and a high endemic level with respect to nosocomial infection control measures? An analysis based on the example of vancomycin-resistant Enterococcus faecium in hematology and oncology departments. GMS Hyg Infect Control. 2017 Aug 28;12:Doc14. doi: 10.3205/dgkh000299. eCollection 2017. PMID: 28890862; PMCID: PMC5574254.
Copy Download .nbib Format: NLM
Share it on

GMS Hyg Infect Control. 2017 Aug 28;12:Doc14. doi: 10.3205/dgkh000299. eCollection 2017.

Where is the difference between an epidemic and a high endemic level with respect to nosocomial infection control measures? An analysis based on the example of vancomycin-resistant Enterococcus faecium in hematology and oncology departments.

GMS hygiene and infection control

Nikos Ulrich, Petra Gastmeier

Affiliations

  1. Institute for Hygiene and Environmental Medicine, Charité - University Medicine, Berlin, Germany.

PMID: 28890862 PMCID: PMC5574254 DOI: 10.3205/dgkh000299

Abstract

Some infection control recommendations distinguish epidemic and endemic levels for infection control. However, it is often difficult to separate long lasting outbreaks from high endemic levels and it remains open, if this distinction is really useful.

Keywords: endemic; haematology; oncology; outbreaks; vancomycin-resistant enterococi

Conflict of interest statement

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

  1. Clin Infect Dis. 2015 Nov 1;61(9):1413-20 - PubMed
  2. J Antimicrob Chemother. 2012 Apr;67(4):832-6 - PubMed
  3. N Engl J Med. 2000 Dec 28;343(26):1925-32 - PubMed
  4. Klin Padiatr. 1998 Jul-Aug;210(4):261-3 - PubMed
  5. Infection. 2011 Feb;39(1):29-34 - PubMed
  6. J Hosp Infect. 2016 Sep;94(1):2-7 - PubMed
  7. J Clin Microbiol. 2001 May;39(5):1781-7 - PubMed
  8. Lancet Infect Dis. 2007 Apr;7(4):282-8 - PubMed
  9. J Antimicrob Chemother. 1997 Oct;40(4):607-8 - PubMed
  10. Clin Infect Dis. 1995 May;20(5):1126-33 - PubMed
  11. Biomed Res Int. 2014;2014:575367 - PubMed
  12. Am J Infect Control. 2007 Dec;35(10 Suppl 2):S165-93 - PubMed
  13. Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55 - PubMed
  14. J Korean Med Sci. 2005 Apr;20(2):169-76 - PubMed
  15. Br J Haematol. 2002 Mar;116(4):826-33 - PubMed
  16. Infect Dis Clin North Am. 2016 Dec;30(4):953-965 - PubMed
  17. Infect Control Hosp Epidemiol. 2001 Apr;22(4):217-9 - PubMed
  18. J Pediatr Hematol Oncol. 2012 Oct;34(7):511-6 - PubMed
  19. J Hosp Infect. 2000 Apr;44(4):294-300 - PubMed
  20. Infect Control Hosp Epidemiol. 1999 Nov;20(11):760-3 - PubMed
  21. JAMA. 2014 Oct 8;312(14):1395-6 - PubMed
  22. J Clin Microbiol. 2000 Feb;38(2):620-4 - PubMed
  23. Infect Control Hosp Epidemiol. 2006 Sep;27(9):984-6 - PubMed
  24. J Clin Microbiol. 2000 Sep;38(9):3317-22 - PubMed
  25. Scand J Infect Dis. 2004;36(11-12):790-4 - PubMed
  26. J Hosp Infect. 1996 Nov;34(3):171-82 - PubMed
  27. Infect Control Hosp Epidemiol. 2002 Aug;23(8):468-70 - PubMed
  28. J Antimicrob Chemother. 2014 May;69(5):1185-92 - PubMed
  29. J Antimicrob Chemother. 2007 Oct;60(4):849-54 - PubMed
  30. Eur J Pediatr. 1998 Jan;157(1):20-7 - PubMed
  31. Leuk Lymphoma. 2014 Jun;55(6):1225-6 - PubMed
  32. Genome Res. 2016 Oct;26(10 ):1388-1396 - PubMed
  33. J Antimicrob Chemother. 2014 Feb;69(2):500-5 - PubMed
  34. BMC Infect Dis. 2011 Oct 13;11:272 - PubMed
  35. Infect Control Hosp Epidemiol. 2006 Sep;27(9):991-3 - PubMed
  36. Infect Control Hosp Epidemiol. 2009 Apr;30(4):338-45 - PubMed
  37. Lancet Oncol. 2014 Dec;15(13):e606-19 - PubMed
  38. Genome Announc. 2016 Aug 18;4(4):null - PubMed
  39. Microb Drug Resist. 2011 Mar;17(1):59-65 - PubMed
  40. Antimicrob Agents Chemother. 1994 Jun;38(6):1363-7 - PubMed
  41. Clin Microbiol Infect. 2008 Sep;14(9):853-7 - PubMed
  42. Onkologie. 2005 Apr;28(4):187-92 - PubMed
  43. Int J Hematol. 2007 Aug;86(2):158-62 - PubMed
  44. Epidemiol Infect. 2016 Jun;144(8):1748-55 - PubMed
  45. Euro Surveill. 2005 Jan 27;10(1):E050127.1 - PubMed
  46. Eur J Haematol. 2007 Sep;79(3):226-33 - PubMed
  47. Clin Microbiol Infect. 2008 May;14 Suppl 5:2-20 - PubMed
  48. FEMS Immunol Med Microbiol. 2002 Jul 12;33(3):179-89 - PubMed
  49. Infect Control Hosp Epidemiol. 1992 Dec;13(12):700-5 - PubMed
  50. Infect Control Hosp Epidemiol. 2016 Jan;37(1):26-35 - PubMed
  51. Infect Control Hosp Epidemiol. 2014 Jul;35(7):876-9 - PubMed
  52. Clin Microbiol Infect. 2007 Sep;13(9):893-901 - PubMed
  53. Pol Arch Med Wewn. 2009 Nov;119(11):712-8 - PubMed
  54. J Med Microbiol. 1997 Feb;46(2):150-6 - PubMed
  55. Scand J Infect Dis. 2014 Aug;46(8):547-54 - PubMed
  56. J Clin Microbiol. 1999 Feb;37(2):413-6 - PubMed
  57. Antimicrob Agents Chemother. 2017 Jan 24;61(2): - PubMed

Publication Types